GlassScriptPhysician profile
Lee R Katzman
NPI 1912297284
$21,139.82
in general payments reported to CMS, 2019-2025
30 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,163 · 2020: $1,709 · 2021: $1,411 · 2022: $2,506 · 2023: $3,481 · 2024: $7,574 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,500 · Food and Beverage: $4,816 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,500.00 |
| Food and Beverage | $4,815.96 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $6,190.53 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Alcon Vision LLC | $4,625.68 | 2019-2025 | Clareon, Argos, Wavelight Refractive Suite |
| Glaukos Corporation | $2,888.11 | 2019-2025 | Iaccess Precision Blade, Idosetr, Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,351.74 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $1,282.55 | 2022-2025 | Envista Mx60 Iol, Miebo, Envista Envy Iol |
| Johnson & Johnson Surgical Vision, INC. | $972.44 | 2019-2025 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Sight Sciences, INC. | $688.31 | 2020-2025 | Omni Surgical System |
| New World Medical,INC. | $627.70 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $509.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $478.82 | 2019-2023 | |
| Allergan, INC. | $411.12 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $236.61 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $162.71 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $144.68 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Shire North American Group INC | $86.44 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $67.58 | 2022-2023 | |
| Ocular Therapeutix, INC. | $65.18 | 2020-2025 | Dextenza |
| Mallinckrodt Hospital Products INC. | $47.98 | 2020 | |
| Abbvie INC. | $45.32 | 2023 | |
| Biotissue Holdings INC. | $40.13 | 2021-2024 | |
| Ivantis, INC | $36.48 | 2020-2021 | |
| Lensar, INC. | $33.01 | 2025 | Lensar Laser System |
| Dompe US, INC. | $25.35 | 2024 | Oxervate |
| Sun Pharmaceutical Industries INC. | $24.77 | 2020 | |
| Staar Surgical Company | $22.88 | 2019 | |
| Harrow Eye, LLC | $22.13 | 2024 | Vevye |
| Tearlab Corp | $20.33 | 2024 | Scoutpro Osmolarity System |
| Thea Pharma INC. | $17.77 | 2024 | Iyuzeh |
| Optos, INC. | $14.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Katzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.